Translate Bio, Inc. Shares Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • June 12th, 2018 • Translate Bio, Inc. • Biological products, (no disgnostic substances) • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
Collaboration and License AgreementCollaboration and License Agreement • June 12th, 2018 • Translate Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement is executed on June 8, 2018 (the “Execution Date”) by and between Translate Bio MA, Inc., with offices at 29 Hartwell Ave, Lexington, MA 02421, USA., a corporation registered under the laws of the State of Delaware (“Translate Bio” or “TB”) and Sanofi Pasteur Inc., a company incorporated under the laws of the state of Delaware, with offices at Discovery Drive, Swiftwater, PA 18370 USA (“Sanofi”). Sanofi and Translate Bio are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.First Amendment to Asset Purchase Agreement • June 12th, 2018 • Translate Bio, Inc. • Biological products, (no disgnostic substances)
Reference is made to the Asset Purchase Agreement by and between Translate Bio, Inc. formerly known as RaNA Therapeutics, Inc. (“Translate Bio”) and Shire Human Genetics Therapies, Inc. (“Shire”) entered into as of December 22, 2016 (the “Agreement”). Capitalized terms used but not defined herein have the respective meanings set forth in the Agreement.
